|
|
|
|
|
|
 |
|
 |
|
|
|
development of novel pharmaceuticals and diagnostics strategies to address key unmet
medical needs in HIV/AIDS |
|
| |
|
| Roche has been committed since 1986 to discovering innovative new therapies and diagnostics aimed at improving the wellbeing of people living with HIV. In 2004, Roche continues at the forefront of efforts to combat HIV infection and AIDS. With the availability of FUZEON, the first fusion inhibitor, there are now four classes of anti-HIV drugs from which to construct effective treatment regimens for pre-treated patients. |
|
| |
|
 |
|
 |
|
| Boosted Invirase is recommended as first-line treatment with 1A rating in new IAS treatment guidelines |
| |
 |
2004 |
| US FDA grants priority review status to Invirase 500 mg |
| |
 |
|
| Filing of Invirase 500 mg in the US and Europe |
| |
|
|
| FUZEON� long-term 96 week safety and efficacy confirmed |
| |
|
|
| FUZEON� 48 week data approved for European label |
| |
|
|
| FUZEON� wins International Prix Galien Award for Innovative Therapies |
| |
|
|
| |
|
|
| |
2003 |
 |
FUZEON� (enfuvirtide), the first HIV fusion inhibitor, receives approval in the US and Europe |
|
|
COBAS AMPLICOR HIV-1 MONITOR� Test Version 1.5 receives approval in the US and Europe |
|
COBAS TaqMan� 48 Analyzer is introduced in the US and Europe with CE-Marked tests for HIV, HBV and HCV launched in Europe |
|
|
|
|
| COBAS TaqMan� Analyzer, Series 96, receives approval in the US |
| |
|
2002 |
| EU approval for boosted saquinavir/ritonavir 1000/100 mg bid |
| |
|
|
AMPLICOR HIV-1 MONITOR� Test Version 1.5 receives US approval
(can additionally detect and quantify non-B HIV subtypes) |
| |
|
| |
|
|
|
2001 |
|
VALCYTE� (valganciclovir) receives US and EU approval for treatment of AIDS-related CMV retinitis |
|
|
|
|
| Phase III studies begin with the first HIV fusion inhibitor |
| |
|
2000 |
| Roche presents data on the first HIV resistance assay using micro-array chip technology |
| |
|
|
|
|
|
1999 |
|
AMPLICOR HIV-1 MONITOR� Ultra Sensitive Method approved (measures down to 50 HIV RNA copies/ml) |
|
Roche initiates research and development collaboration with Trimeris Inc on inhibition of HIV fusion |
| |
|
| VIRACEPT� (nelfinavir) approved in EU |
| |
|
1998 |
|
| INVIRASE � wins International Prix Galien Award for Innovative Therapies |
| |
|
| |
|
|
1997 |
|
Approval for new formulation of saquinavir: FORTOVASE� |
| |
|
|
| AMPLICOR HIV-1 MONITOR� Test approved (measures down to 400 HIV RNA copies/mL) |
| |
|
1996 |
|
| |
|
|
|
| 1995 |
|
INVIRASE� (saquinavir), the first protease inhibitor, introduced |
|
|
| CYMEVENE�/CYTOVENE� (ganciclovir) capsules approved for treatment of CMV retinitis in HIV |
| |
|
1994 |
|
|
|
|
|
| 1992 |
|
HIVID� (zalcitabine) approved |
|
Qualitative AMPLICOR� PCR test approved |
| |
|
| IV ganciclovir approved for HIV induction therapy |
| |
|
1989 |
|
| |
|
|
| |
1987 |
|
First Roche HIV antibody test introduced |
|
|
|
| Roche initiates HIV protease inhibitor project |
| |
|
1986 |
|
| ROFERON-A� (interferon alfa-2a) approved for Kaposi's sarcoma |
| |
 |
|
|
| |
|
|
|
|
|
|
|
|
|
Roche - a continued commitment to research and development in HIV/AIDS |
|
|
| |
|
|
|
|
|
|
|
|
|
|
